Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Evaluate Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy of PF-114 for Oral Administration in Adults With Ph+ Chronic Myeloid Leukemia, Which is Resistant to the 2-nd Generation Bcr-Abl Inhibitors or Has T315I Mutation in the BCR-ABL Gene

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02885766
Recruitment Status : Recruiting
First Posted : August 31, 2016
Last Update Posted : February 15, 2019
Sponsor:
Collaborators:
OCT Rus, LLC
Data Matrix Solutions
Skolkovo Innovation Center
Information provided by (Responsible Party):
Fusion Pharma LLC

Brief Summary:
A multicenter, open label cohort Phase 1 dose finding study to evaluate tolerability, safety, pharmacokinetics and preliminary efficacy of PF-114 for oral administration in adult patients with Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML), which is resistant to the 2-nd generation Bcr-Abl inhibitors or has T315I mutation in the BCR-ABL gene.

Condition or disease Intervention/treatment Phase
Chronic Myeloid Leukemia Leukemia, Myelogenous, Chronic, BCR-ABL Positive Drug: PF-114 Phase 1 Phase 2

Detailed Description:

PF-114 is a low molecular inhibitor of a Bcr-Abl kinase activity, which is active with respect to native and mutated forms of this enzyme with mutations in Abl kinase domain. Preclinical in vitro and in vivo studies have demonstrated the ability of PF-114 to inhibit wild Bcr-Abl type and with T315I mutation, as well as other kinds of Bcr-Abl with mutations in kinase domain, including combined mutations.

In contrast to ponatinib, PF-114 is being developed to increase the action selectivity with respect to Bcr-Abl, which potentially should increase safety of drug application in people. The results of performed preclinical studies confirmed improved selectivity of PF-114 action with respect to Bcr-Abl kinases as compared to ponatinib.

Indication:

Adult patients with Ph+ CML in chronic phase (CP) or accelerated phase (AP) resistant to previous treatment with at least one 2-nd generation inhibitor of Bcr-Abl (dasatinib, nilotinib, bosutinib) or intolerant of approved Bcr-Abl inhibitors or with T315I mutation in the BCR-ABL gene


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 44 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicenter, Open Label Cohort Phase 1 Dose Finding Study to Evaluate Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy of PF-114 Mesylate for Oral Administration in Adult Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia (CML), Which is Resistant to the 2-nd Generation Bcr-Abl Inhibitors or Has T315I Mutation in the BCR-ABL Gene
Actual Study Start Date : July 2016
Actual Primary Completion Date : June 2018
Estimated Study Completion Date : April 2019


Arm Intervention/treatment
Experimental: PF-114

PF-114 From 50 mg up to the MTD. Dose escalation for each next cohort is conducted by increasing the dose by 20 % (or the closest lower level, which is a multiple of 25 mg) if there are Grade 3 ADRs according to NCI CTC AE v.4 without reaching а MTD. An increase of the dose by 40 % is applied if there were Grade 2 ADRs. In the absence of Grade 2 or 3 ADRs an increase of 100 % is applied.

When the dose reaches 400 mg/day, the following increase in dose can be made after discussing results of safety findings of PF-114 between the Investigators and the Sponsor.

Orally, once daily

Drug: PF-114



Primary Outcome Measures :
  1. DLTs during the first cycle of therapy [ Time Frame: 1-st Cycle of Therapy - 28 days ]
    To study the dose-limiting toxicities (DLTs) of PF-114 mesylate in the target patient population during the 1-st cycle of treatment

  2. MTD [ Time Frame: 1-st Cycle of Therapy - 28 days ]

    Primary Objectives:

    To determine the maximum tolerated dose (MTD) of PF-114 in the target patient population.



Secondary Outcome Measures :
  1. The incidence of AEs [ Time Frame: through study completion, an average of 1 year ]
    To assess the safety and tolerability of PF-114 in the target patient population

  2. Cmax for oral PF-114 in the target patient population [ Time Frame: 31 days ]
  3. Tmax for oral PF-114 in the target patient population [ Time Frame: 31 days ]
  4. AUC0-t for oral PF-114 in the target patient population [ Time Frame: 31 days ]
  5. AUC0-∞ for oral PF-114 in the target patient population [ Time Frame: 31 days ]
  6. T1/2 for oral PF-114 in the target patient population [ Time Frame: 31 days ]
  7. CL/F for oral PF-114 in the target patient population [ Time Frame: 31 days ]
  8. Vd/F for single and multiple dosing for oral PF-114 in the target patient population [ Time Frame: 31 days ]
  9. Ctrough for multiple dosing for oral PF-114 in the target patient population [ Time Frame: 31 days ]
  10. Hematological response to the treatment based on European LeukemiaNet criteria, 2013. [ Time Frame: through study completion, an average of 1 year ]

    Hematological response is evaluated on Day 1 of each therapy cycle

    Full hematologic response:

    Leukocytes < 10 х 109 /L Basophils < 5 % Thrombocytes < 450 х 109 /L No myelocytes, promyelocyts, myeloblasts in the differential Absence of splenomegaly - spleen non palpable


  11. Molecular response - the level of BCR-ABL transcripts in the peripheral blood, determined by the method of quantitative polymerase chain reaction (qPCR) using the international scale. [ Time Frame: through study completion, an average of 1 year ]
    Molecular response is evaluated on Day 1 of Cycles 2, 4, 7, 10. For cycles > 12, the molecular response will be evaluated once in 3 months, where the procedure is carried out for the first time during Cycle 13.

  12. Cytogenetic response evaluated using the chromosome banding method (in situ (FISH) fluorescence hybridization is allowed only if the chromosome banding method cannot provide enough information). [ Time Frame: through study completion, an average of 1 year ]
    Cytogenetic response is evaluated on Day 1, Cycles 4, 7, 13. Then if the level of BCR-ABL transcripts exceeds the level of 0.1% using the qPCR method using the international scale, cytogenetic response is evaluated no earlier than in 3 months after the previous cytogenetic analysis. After the complete cytogenetic response has been reached (CCyR), cytogenetic analysis will be carried out every 12 months.


Other Outcome Measures:
  1. Pharmacodynamic response criterion to PF-114 (change in the level of pCrkL in PBL during therapy compared to baseline level) [ Time Frame: 20 months ]
    To assess pharmacodynamic response to PF-114 mesylate in patients who are not in complete hematologic response upon enrollment into the study by measuring the difference of pCrkL levels in peripheral blood leukocytes (PBL) during therapy compared to baseline

  2. The number of patients who satisfy the pharmacodynamic response criterion depending on the mutation status of BCR-ABL [ Time Frame: 20 months ]
  3. The number of patients who satisfy the hematologic response depending on the mutation status of BCR-ABL [ Time Frame: 20 months ]
  4. The number of patients who satisfy the cytogenetic response depending on the mutation status of BCR-ABL [ Time Frame: 20 months ]
  5. The number of patients who satisfy the molecular response depending on the mutation status of BCR-ABL [ Time Frame: 20 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Patients must meet all of the following criteria in order to be eligible for participation in the study:

  1. Able to give written informed consent;
  2. Male or female patient ≥ 18 years old;
  3. Confirmed diagnosis of CML in chronic or accelerated phase according to European LeukemiaNet guideline as of 2013;
  4. Available information regarding resistance to the therapy with least one 2-nd generation Bcr-Abl inhibitor (dasatinib or nilotinib or bosutinib), or intolerance of approved Bcr-Abl inhibitors, or presence of T315I mutation irrespective of treatment history;
  5. In case of previous history of blast crisis phase of CML at least 6 months are required to pass after the end of blast crisis phase before the first dose of PF-114;
  6. ECOG performance status ≤ 2 (see Appendix 2);
  7. Adequate renal function defined as serum creatinine ≤ 1.5 times upper limit of normal (ULN);
  8. Adequate hepatic function defied as:

    • serum bilirubin ≤ 1.5 X ULN unless a patient is diagnosed with Gilbert's syndrome;
    • serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 X ULN;
    • alkaline phosphatase ≤ 2.5 X ULN;
    • INR ≤ 1.5 X ULN;
  9. Adequate cardiac function defined as LVEF > 40 % by echocardiogram;
  10. QTcF < 470 ms;
  11. Patient has recovered (to Grade 1 or less according to NCI CTCAE V 4.0) from toxicities (excluding alopecia) associated with any prior treatments;
  12. Female patients of childbearing potential and male patients who have female partners of childbearing potential must agree with abstinence from sexual relations or use effective methods of contraception throughout participation in the study;
  13. Ability to comply with study procedures in the Investigator's opinion.

Exclusion Criteria:

Patients must not meet any of the following criteria in order to be eligible for participation in the study:

  1. Use of the following previous therapy:

    1. chemotherapy ≤ 21 days (except hydroxyurea for which washout is not required) prior to the first dose of PF-114 mesylate; оr nitrosoureas оr mitomycin С ≤ 42 days prior to the first dose of PF-114 mesylate;
    2. approved tyrosine kinase inhibitors or investigational agents ≤ 4 days prior to the first dose of PF-114;
    3. radiotherapy ≤ 28 days prior to the first dose of PF-114 ;
    4. autologous оr allogeneic stem сеll transplant < 90 days prior to enrollment;
  2. Significant uncontrolled cardiac disease;
  3. Sustained uncontrolled hypertension ≥ Grade 2 (according to NCI CTC AE v4);
  4. Patient is taking medicinal products known to prolong the QT interval on the electrocardiogram, unless they are absolutely necessary in the opinion of the investigator;
  5. Evidence of on-going graft versus host disease (GVHD), or GVHD requiring immunosuppressive therapy. Patients should be off immunosuppressive therapy for prophylaxis and/or treatment for at least 14 days prior to the first dose of PF-114;
  6. Major surgery within 35 days prior to enrollment;
  7. Uncontrolled intercurrent illness including, but not limited to the following: active systemic infection, uncontrolled seizure disorder, psychiatric or social circumstances that would limit compliance with study requirements or misrepresent results of the study;
  8. Patient is unable to swallow study drug or has gastro-intestinal disorders that could negatively affect oral absorption of PF-114 ;
  9. Any malignancy other than CML within the past 3 years (except for non-melanoma skin cancer or cervical cancer in situ).
  10. Pregnancy or breast feeding.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02885766


Contacts
Layout table for location contacts
Contact: Veronika Shulgina, PhD +7 916 815 05 44 veronika.shulgina@fusion-pharma.com
Contact: Ghermes Chilov, PhD +7 916 307 48 42 ghermes@fusion-pharma.com

Locations
Layout table for location information
Russian Federation
Federal Haematological Scientific Center Recruiting
Moscow, Russian Federation, 125167
Contact: Anna Turkina, Professor    7 495 612 44 72    turkianna@yandex.ru   
Contact: Oleg Shukhov, PhD    +7 985 287 12 69    shuhov@list.ru   
Moscow City Centre of Hematology based on City Hospital named by S.Botkin Recruiting
Moscow, Russian Federation, 125284
Contact: Olga Vinogradova, Prof. DMSci    +7(495)945-97-61    olgavinz@mail.ru   
Federal Almazov North-West Medical Research Centre Recruiting
St. Petersburg, Russian Federation
Contact: Elza Lomaia, MD, PhD    +7 981 936 16 67    lomelza@gmail.com   
Sponsors and Collaborators
Fusion Pharma LLC
OCT Rus, LLC
Data Matrix Solutions
Skolkovo Innovation Center
Investigators
Layout table for investigator information
Principal Investigator: Anna Turkina, Professor Federal Haematological Scientific Center

Additional Information:
Publications of Results:
Layout table for additonal information
Responsible Party: Fusion Pharma LLC
ClinicalTrials.gov Identifier: NCT02885766     History of Changes
Other Study ID Numbers: PF-114-01
First Posted: August 31, 2016    Key Record Dates
Last Update Posted: February 15, 2019
Last Verified: February 2019
Keywords provided by Fusion Pharma LLC:
CML
Myeloid leukaemia chronic
CML progression
Chronic phase chronic myeloid leukemia
PF-114
Cytogenetic response CCyR
Major molecular response MMR
Complete molecular response CMR
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2-nd generation Bcr-Abl inhibitors resistant
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia
Leukemia, Myeloid
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Neoplasms by Histologic Type
Neoplasms
Myeloproliferative Disorders
Bone Marrow Diseases
Hematologic Diseases